Madrigal Pharmaceuticals, Inc. reported $1.28B of revenue over the trailing twelve months, +149% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.28B (to Q2 2026). Net income: −$325M, trailing twelve months to Q2 2026. Free cash flow: −$207M, trailing twelve months to Q2 2026. Operating margin: −26%, trailing twelve months to Q2 2026.

MDGLMadrigal Pharmaceuticals, Inc.

Healthcare

$471.93+7.3% 1Y

$471.93

$412.3552 weeks$602.83

MDGL as reported

Madrigal Pharmaceuticals, Inc. reported $1.28B of revenue over the trailing twelve months, +149% on the year before. 9 reported series are charted on this page, each one as filed.

$1.28B

Revenue, trailing twelve months · to Q2 2026 · +149% against the twelve months before

Net income: −$325M
Net income · +15% year on year · trailing twelve months to Q2 2026
Free cash flow: −$207M
Free cash flow · −33% year on year · trailing twelve months to Q2 2026
Operating margin: −26%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MDGL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.28B	+149%	Q2 2026
Net income	−$325M	+15%	Q2 2026
EPS	−$13.98	+20%	Q2 2026
Operating margin	−26%	n/a	Q2 2026
Net margin	−26%	n/a	Q2 2026
ROE	−53%	n/a	Q2 2026
ROA	−24%	n/a	Q2 2026
ROIC	−148%	n/a	Q2 2026
Free cash flow	−$207M	−33%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.